Logo

Proteome Systems Licenses Ovarian Cancer Protein from Westmead Millennium Institute

Oct 20, 2004

NEW YORK, Oct. 20 (GenomeWeb News) - Proteome Systems of Australia has licensed a potential biomarker for ovarian cancer from the Children's Hospital at Westmead and Westmead Millennium Institute of Sydney, the company said today.

 

Proteome Systems plans to evaluate the protein biomarker for inclusion in a non-invasive test for the early detection of ovarian cancer the company has been developing.

 

The company said it is currently evaluating two other proteins identified from plasma samples using its proteomics technology

Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.